title: Cell mediated immune status in malignancy--pretherapy and post-therapy assessment.
abstract: Twenty-eight cases of malignancies of different kinds were studied to assess T-cell activity and population before and after institution of therapy. Fifteen cases were diagnosed as non-metastasising squamous cell carcinoma of larynx, pharynx, laryngopharynx, hypopharynx and tonsils. Seven cases were non-metastasising infiltrating duct carcinoma of breast and 6 cases were non-Hodgkin's lymphoma (NHL). It was observed that 3 out of 15 cases (20%) of squamous cell carcinoma cases were Mantoux test (MT) negative with a T-cell population of less than 40%, 2 out of 7 cases (28.6%) of infiltrating duct carcinoma of breast were MT negative with a T-cell population of less than 40% and 3 out of 6 cases (50%) of NHL were MT negative with a T-cell population of less than 40%. The normal controls, consisting of apparently normal healthy adults, had a T-cell population of more than 40% and were all MT positive. The patients who showed a negative skin test and a T-cell population less than 40% were further subjected to assessment of T-cell population and activity after appropriate therapy, and clinical cure of the disease. It was observed that 2 out of 3 cases (66.66%) of squamous cell carcinomas, 2 out of 2 cases (100%) of adenocarcinomas and one out of 3 cases (33.33%) of NHL showed positive conversion with a T-cell population of more than 40%.
authors.affiliation: Department of Pathology, Medical College, Calcutta.
authors.forename: S K
authors.initials: SK
authors.lastname: Sinha
authors.forename: N
authors.initials: N
authors.lastname: Basu
authors.forename: K
authors.initials: K
authors.lastname: Basu
authors.forename: S
authors.initials: S
authors.lastname: Sanyal
authors.forename: P K
authors.initials: PK
authors.lastname: Sur
authors.forename: K K
authors.initials: KK
authors.lastname: Bhattacharyya
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy / Q000276:immunology*; D018270:Carcinoma, Ductal, Breast / Q000188:drug therapy / Q000276:immunology*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy / Q000276:immunology*; D005260:Female; D005500:Follow-Up Studies; D006258:Head and Neck Neoplasms / Q000188:drug therapy / Q000276:immunology*; D006801:Humans; D007111:Immunity, Cellular / Q000187:drug effects / Q000502:physiology; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D011379:Prognosis
chemical_list: D000970:Antineoplastic Agents